Yoshiro Nakahara

Learn More
OBJECTIVES Programmed cell death-ligand 1 (PD-L1) expressed in tumor tissues is a key molecule for immune suppression, given its role in immune checkpoints. The significance and implication of soluble PD-L1 (sPD-L1) in the blood of lung cancer patients remain unknown. PATIENTS AND METHODS Blood samples were prospectively collected from patients with(More)
BACKGROUND Bevacizumab requires some unique eligibility criteria, such as absence of hemoptysis and major blood vessel invasion by the tumor. The prognostic impact of these bevacizumab-specific criteria has not been evaluated. METHODS Patients with stage IIIB/IV, non-squamous non-small cell lung cancer who started chemotherapy before the approval of(More)
BACKGROUND Prior supplementation with folic acid and vitamin B12 is required to reduce pemetrexed therapy toxicity; the recommended lead-in time is at least 7 days. On the basis of previous pharmacokinetic and clinical studies, we hypothesized that the lead-in time could be shortened to 24 hours, enabling earlier commencement of standard chemotherapy; thus,(More)
The weight and size of 12 main internal organs of Normal Japanese were measured at the Tokyo Medical Examiners Office, where the autopsies have been carried out on sudden death cases. This report selected, 5,600 cases with little or no pathological body change, from approximately 18,000 total autopsy cases, during the period of 1970-1980. The organs were(More)
Small-cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation typically manifests as a transformation occurring after EGFR tyrosine kinase inhibitor therapy for adenocarcinoma with EGFR mutation, whereas primary small-cell lung cancer showing EGFR mutation is extremely rare. Second biopsy of EGFR-mutated tumor has been broadly recognized(More)
De novo rearrangements incidentally found at prenatal diagnosis may carry an increased risk of abnormal outcome. Situations in which the paternal chromosomes cannot be analyzed (e.g., artificial insemination, nonpaternity, deceased or otherwise unavailable father) are only "possibly" de novo. In our series of 23,495 prenatal diagnoses we unexpectedly found(More)
BACKGROUND Malignant pleural effusion (MPE) can occur during the progression of various cancers. However, factors, such as the incidence of MPE associated with different types of cancers and its potential for diagnosing previously undetected cancers, are unknown. Moreover, MPE may accompany potentially curable cancers or those with a favorable survival(More)
Pegfilgrastim is a long-acting granulocyte colony-stimulating factor formulation that has been approved for the prevention of febrile neutropenia. We herein report a case of interstitial pneumonia following administration of pegfilgrastim. A 65-year-old man with stage IV small-cell lung cancer was treated with carboplatin and etoposide as third-line(More)
Background Previous study indicated that an optional anti-cancer drug for the treatment of small-cell lung cancer (SCLC) is amrubicin. However, no prospective studies have evaluated amrubicin in chemo-naive elderly or poor-risk patients with SCLC. Therefore, this study aimed to evaluate the efficacy of amrubicin as first-line chemotherapy for elderly or(More)